Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions

American Journal of Gastroenterology

Volumn 109, Issue 8, 2014, Pages 1205-1214

  Lochhead, Paul ^a   Chan, Andrew T ^b,c   Giovannucci, Edward ^c,d   Fuchs, Charles S ^c   Wu, Kana ^d   Nishihara, Reiko ^c,d   O'Brien, Michael ^e   Ogino, Shuji ^c,d,f  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; CELL TRANSFORMATION, NEOPLASTIC; COLONIC POLYPS; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; HUMANS; HYPERPLASIA; PHENOTYPE; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; RISK FACTORS;

EID: 84905591645     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.153     Document Type: Article

References (174)

1. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8 : 686-700.
2. Fridman WH, Pages F, Sautes-Fridman C et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12 : 298-306.
3. Galon J, Franck P, Marincola FM et al. Cancer classifi cation using the Immunoscore: a worldwide task force. J Transl Med 2012; 10 : 205.
4. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving fi eld of molecular pathological epidemiology. J Natl Cancer Inst 2010; 102 : 365-7.
5. Ogino S, Chan AT, Fuchs CS et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary fi eld. Gut 2011; 60 : 397-411.
6. Hughes LA, Simons CC, van den Brandt PA et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One 2011; 6 : e18571.
7. Spitz MR, Caporaso NE, Sellers TA. Integrative cancer epidemiology-the next generation. Cancer Discov 2012; 2 : 1087-90.
8. Koshiol J, Lin SW. Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol 2012; 22 : 520-30.
9. Amirian ES, Petrosino JF, Ajami NJ et al. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer 2013; 8 : 42.
10. Ogino S, Lochhead P, Chan AT et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013; 26 : 465-84.
11. Ogino S, Lochhead P, Giovannucci E et al. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene; advance online publication, 24 June 2013; doi:10.1038/onc.2013.244 (e-pub ahead of print).
12. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation status, and colorectal cancer survival. N Engl J Med 2012; 367 : 1596-606.
13. Nishihara R, Lochhead P, Kuchiba A et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013; 309 : 2563-71.
14. Yamauchi M, Lochhead P, Imamura Y et al. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013; 22 : 1142-52.
15. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int 2011; 2011 : 902674.
16. Hughes LA, Khalid-de Bakker CA, Smits KM et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012; 1825 : 77-85.
17. Iwagami S, Baba Y, Watanabe M et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol 2012; 19 : 2726-32.
18. Limburg PJ, Limsui D, Vierkant RA et al. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev 2012; 21 : 681-4.
19. Hughes LA, Williamson EJ, van Engeland M et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. Int J Epidemiol 2012; 41 : 1060-72.
20. Ku CS, Cooper DN, Wu M et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012; 25 : 1055-68.
21. Rex DK, Ahnen DJ, Baron JA et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012; 107 : 1315-29.
22. Fini L, Grizzi F, Laghi L. Adaptive and innate immunity, non clonal players in colorectal cancer progression. In: Ettarh R (ed). Colorectal Cancer Biology-From Genes to Tumor. InTech: Rijeka, Croatia, 2012, pp. 323-40.
23. Gay LJ, Mitrou PN, Keen J et al. Dietary, lifestyle and clinico-pathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk Study. J Pathol 2012; 228 : 405-15.
24. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol 2012; 9 : 561-70.
25. Dogan S, Shen R, Ang DC et al. Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012; 18 : 6169-77.
26. Shanmuganathan R, Nazeema Banu B, Amirthalingam L et al. Conventional and nanotechniques for DNA methylation profi ling. J Mol Diagn 2013; 15 : 17-26.
27. Rosty C, Young JP, Walsh MD et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013; 26 : 825-34.
28. Weijenberg MP, Hughes LA, Bours MJ et al. The mTOR pathway and the role of energy balance throughout life in colorectal cancer etiology and prognosis: unravelling mechanisms through a multidimensional molecular epidemiologic approach. Curr Nutr Rep 2013; 2 : 19-26.
29. Buchanan DD, Win AK, Walsh MD et al. Family history of colorectal cancer in BRAF p.V600E mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev 2013; 22 : 917-26.
30. Burnett-Hartman AN, Newcomb PA, Potter JD et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013; 73 : 2863-72.
31. Alvarez MC, Santos JC, Maniezzo N et al. MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults. World J Gastroenterol 2013; 19 : 3043-51.
32. Hagland HR, Berg M, Jolma IW et al. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg 2013; 30 : 12-25.
33. Abbenhardt C, Poole EM, Kulmacz RJ et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet 2013; 4 : 140-9.
34. Bae JM, Kim JH, Cho NY et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer 2013; 109 : 1004-12.
35. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA 2013; 310 : 2401-2.
36. Zhu Y, Yang SR, Wang PP et al. Infl uence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer 2014; 110 : 1359-66.
37. Hoffmeister M, Blaker H, Kloor M et al. Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 2013; 22 : 2303-11.
38. Jacobs RJ, Voorneveld PW, Kodach LL et al. Cholesterol metabolism and colorectal cancers. Curr Opin Pharmacol 2012; 12 : 690-5.
39. Shaheen NJ. Editorial: what is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol 2014; 109 : 345-7.
40. Brandstedt J, Wangefjord S, Nodin B et al. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defi ned by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer 2014; 14 : 371.
41. Coppede F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol 2014; 1-14.
42. Bishehsari F, Mahdavinia M, Vacca M et al. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol 2014; 20 : 6055-72.
43. Morikawa T, Kuchiba A, Yamauchi M et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011; 305 : 1685-94.
44. Gruber SB, Moreno V, Rozek LS et al. Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther 2007; 6 : 1143-7.
45. Slattery ML, Herrick J, Curtin K et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res 2010; 70 : 1479-85.
46. Garcia-Albeniz X, Nan H, Valeri L et al. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis 2013; 34 : 292-8.
47. Ogino S, Galon J, Fuchs CS et al. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8 : 711-9.
48. Ogino S, Nosho K, Meyerhardt JA et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008; 26 : 5713-20.
49. Caporaso NE. Why precursors matter. Cancer Epidemiol Biomarkers Prev 2013; 22 : 518-20.
50. Ahn J, Sinha R, Pei Z et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105 : 1907-11.
51. Kostic AD, Chun EY, Robertson L et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14 : 207-15.
52. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell 2011; 144 : 986-98.
53. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12 : 621-8.
54. Ogino S, Giovannucci E. Commentary: Lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. In J Epidemiol 2012; 41 : 1072-4.
55. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487 : 330-7.
56. Hammerman PS, Hayes DN, Wilkerson MD et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489 : 519-25.
57. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490 : 61-70.
58. Imamura Y, Morikawa T, Liao X et al. Specifi c mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-type colorectal cancers. Clin Cancer Res 2012; 18 : 4753-63.
59. Chen CC, Er TK, Liu YY et al. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013; 8 : e55793.
60. Edin S, Wikberg ML, Dahlin AM et al. The distribution of macrophages with a m1 or m2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012; 7 : e47045.
61. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the Immunoscore in the classifi cation of malignant tumors. J Pathol 2014; 232 : 199-209.
62. Febbo PG, Ladanyi M, Aldape KD et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011; 9 (Suppl 5) : S1-32; quiz S33.
63. Ogino S, Goel A. Molecular classifi cation and correlates in colorectal cancer. J Mol Diagn 2008; 10 : 13-27.
64. Zlobec I, Bihl MP, Schwarb H et al. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127 : 367-80.
65. Guastadisegni C, Colafranceschi M, Ottini L et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010; 46 : 2788-98.
66. Myers MB, Wang Y, McKim KL et al. Hotspot oncomutations: implications for personalized cancer treatment. Expert Rev Mol Diagn 2012; 12 : 603-20.
67. Gavin P, Colangelo LH, Fumagalli D et al. Mutation profi ling and microsatellite instability in Stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18 : 6531-41.
68. Curtin K, Samowitz WS, Ulrich CM et al. Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer 2011; 63 : 357-66.
69. Li Q, Peng Z, Huang C et al. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res 2013; 19 : 62-72.
70. Jeon JY, Meyerhardt JA. Energy in and energy out: what matters for survivors of colorectal cancer? J Clin Oncol 2012; 30 : 7-10.
71. Belt EJ, Brosens RP, Delis-van Diemen PM et al. Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol 2012; 19 : S682-692.
72. Waldron L, Ogino S, Hoshida Y et al. Expression profi ling of archival tissues for long-term health studies. Clin Cancer Res 2012; 18 : 6136-46.
73. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58 : 90-6.
74. Zlobec I, Bihl M, Foerster A et al. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high,-low, and-negative colorectal cancers based on protein marker expression and molecular features. J Pathol 2011; 225 : 336-43.
75. Wu C, Bekaii-Saab T. CpG island methylation, microsatellite instability, and BRAF mutations and their clinical application in the treatment of colon cancer. Chemother Res Prac 2012; 2012 : 359041.
76. Liao X, Morikawa T, Lochhead P et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18 : 2257-68.
77. Phipps AI, Buchanan DD, Makar KW et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108 : 1757-64.
78. Sethi S, Ali S, Phillip PA et al. Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci 2013; 14 : 14771-84.
79. Wangefjord S, Sundstrom M, Zendehrokh N et al. Sex differences in the prognostic signifi cance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol Sex Differ 2013; 4 : 17.
80. Funkhouser WK, Lubin IM, Monzon FA et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the Association for Molecular Pathology. J Mol Diagn 2012; 14 : 91-103.
81. Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology 2012; 143 : 1442-60 e1.
82. Colussi D, Brandi G, Bazzoli F et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013; 14 : 16365-85.
83. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96 : 8681-6.
84. Hinoue T, Weisenberger DJ, Lange CP et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22 : 271-82.
85. Dahlin AM, Henriksson ML, Van Guelpen B et al. Colorectal cancer prognosis depends on T-cell infi ltration and molecular characteristics of the tumor. Mod Pathol 2011; 24 : 671-82.
86. Zlobec I, Bihl MP, Foerster A et al. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology 2012; 61 : 777-87.
87. Zlobec I, Bihl MP, Foerster A et al. Stratifi cation and prognostic relevance of Jass's molecular classifi cation of colorectal cancer. Front Oncol 2012; 2 : 7.
88. Yamamoto E, Suzuki H, Yamano HO et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol 2012; 181 : 1847-61.
89. Yang Q, Dong Y, Wu W et al. Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation. Nat Commun 2012; 3 : 1206.
90. Beggs AD, Jones A, El-Bahwary M et al. Whole-genome methylation analysis of benign and malignant colorectal tumours. J Pathol 2013; 229 : 697-704.
91. Karpinski P, Walter M, Szmida E et al. Intermediate-and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and-zero) in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013; 22 : 201-8.
92. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013; 5 : 676-713.
93. Dawson H, Galvan JA, Helbling M et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repairdefi ciency. Int J Cancer 2014; 134 : 2342-51.
94. Mouradov D, Domingo E, Gibbs P et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specifi c driver mutations. Am J Gastroenterol 2013; 108 : 1785-93.
95. Kitkumthorn N, Mutirangura A. Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenet 2012; 2 : 315-30.
96. Ibrahim AE, Arends MJ, Silva AL et al. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 2011; 60 : 499-508.
97. Sunami E, de Maat M, Vu A et al. LINE-1 hypomethylation during primary colon cancer progression. PLoS One 2011; 6 : e18884.
98. Ogino S, Kawasaki T, Kirkner GJ et al. CpG island methylator phenotypelow (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8 : 582-8.
99. Barault L, Charon-Barra C, Jooste V et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68 : 8541-6.
100. Kim JH, Shin SH, Kwon HJ et al. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455 : 485-94.
101. Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16 : 1845-55.
102. Donada M, Bonin S, Barbazza R et al. Management of stage II colon cancer-the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 2013; 13 : 36.
103. Samadder NJ, Vierkant RA, Tillmans LS et al. Associations between colorectal cancer molecular markers and pathways with clinico-pathologic features in older women. Gastroenterology 2013; 145 : 348-56.
104. Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008; 100 : 1734-8.
105. Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011; 117 : 1847-54.
106. Antelo M, Balaguer F, Shia J et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One 2012; 7 : e45357.
107. Palmqvist R, Wikberg ML, Ling A et al. The association of immune cell infi ltration and prognosis in colorectal cancer. Curr Colorectal Cancer Rep 2014; 9 : 372-9.
108. Di Caro G, Marchesi F, Laghi L et al. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 2013; 17 : 1088-95.
109. Schreibman IR, Baker M, Amos C et al. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol 2005; 100 : 476-90.
110. Voorham QJ, Rondagh EJ, Knol DL et al. Tracking the molecular features of nonpolypoid colorectal neoplasms: a systematic review and metaanalysis. Am J Gastroenterol 2013; 108 : 1042-56.
111. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319 : 525-32.
112. Maltzman T, Knoll K, Martinez ME et al. Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 2001; 121 : 302-9.
113. Burrell RA, McClelland SE, Endesfelder D et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013; 494 : 492-6.
114. O' Brien MJ, Winawer SJ, Zauber AG et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98 : 371-9.
115. Baker SJ, Preisinger AC, Jessup JM et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50 : 7717-22.
116. Jones AM, Thirlwell C, Howarth KM et al. Analysis of copy number changes suggests chromosomal instability in a minority of large colorectal adenomas. J Pathol 2007; 213 : 249-56.
117. Fodde R, Kuipers J, Rosenberg C et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001; 3 : 433-8.
118. Nishida N, Nagasaka T, Kashiwagi K et al. High copy amplifi cation of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 2007; 6 : 525-33.
119. Baba Y, Nosho K, Shima K et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 2009; 11 : 418-25.
120. Ricciardiello L, Baglioni M, Giovannini C et al. Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res 2003; 63 : 7256-62.
121. Nosho K, Shima K, Kure S et al. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia 2009; 11 : 87-95.
122. Rosty C, Hewett DG, Brown IS et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol 2013; 48 : 287-302.
123. Kuilman T, Michaloglou C, Mooi WJ et al. The essence of senescence. Genes Dev 2010; 24 : 2463-79.
124. Wajapeyee N, Serra RW, Zhu X et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132 : 363-74.
125. Rosenberg DW, Yang S, Pleau DC et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007; 67 : 3551-4.
126. Torlakovic E, Skovlund E, Snover DC et al. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 2003; 27 : 65-81.
127. Lieberman DA, Rex DK, Winawer SJ et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143 : 844-57.
128. Dhir M, Yachida S, Van Neste L et al. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. Int J Cancer 2011; 129 : 1889-98.
129. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol 2013; 11 : 760-7; quiz e54-5.
130. Bettington M, Walker N, Clouston A et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62 : 367-86.
131. Nosho K, Irahara N, Shima K et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3 : e3698.
132. Kambara T, Simms LA, Whitehall VL et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53 : 1137-44.
133. Whitehall VL, Walsh MD, Young J et al. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001; 61 : 827-30.
134. Ogino S, kawasaki T, Kirkner GJ et al. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56 : 1409-16.
135. Huang CS, Farraye FA, Yang S et al. The clinical signifi cance of serrated polyps. Am J Gastroenterol 2011; 106 : 229-40; quiz 241.
136. Martinez ME, Maltzman T, Marshall JR et al. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999; 59 : 5181-5.
137. Wark PA, Van der Kuil W, Ploemacher J et al. Diet, lifestyle and risk of K-ras mutation-positive and-negative colorectal adenomas. Int J Cancer 2006; 119 : 398-405.
138. Einspahr JG, Martinez ME, Jiang R et al. Associations of Ki-ras protooncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev 2006; 15 : 1443-50.
139. van den Donk M, van Engeland M, Pellis L et al. Dietary folate intake in combination with MTHFR C677T genotype and promoter methylation of tumor suppressor and DNA repair genes in sporadic colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2007; 16 : 327-33.
140. Martinez F, Fernandez-Martos C, Quintana MJ et al. APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study. Clin Transl Oncol 2011; 13 : 664-71.
141. Koestler DC, Li J, Baron JA et al. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Mod Pathol 2014; 27 : 145-55.
142. Samowitz WS, Albertsen H, Sweeney C et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98 : 1731-8.
143. Curtin K, Samowitz WS, WolffRK et al. Somatic alterations, metabolizing genes and smoking in rectal cancer. Int J Cancer 2009; 125 : 158-64.
144. Limsui D, Vierkant RA, Tillmans LS et al. Cigarette smoking and colorectal cancer risk by molecularly defi ned subtypes. J Natl Cancer Inst 2010; 102 : 1012-22.
145. Rozek LS, Herron CM, Greenson JK et al. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010; 19 : 838-43.
146. Nishihara R, Morikawa T, Kuchiba A et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classifi cation. Am J Epidemiol 2013; 178 : 84-100.
147. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472 : 90-4.
148. Frankel A. Formalin fi xation in the '-omic's era: a primer for the surgeon-scientist. ANZ J Surg 2012; 82 : 395-402.
149. Klopfleisch R, Weiss AT, Gruber AD. Excavation of a buried treasure-DNA, mRNA, miRNA and protein analysis in formalin fi xed, paraffin embedded tissues. Histol Histopathol 2011; 26 : 797-810.
150. Legres LG, Janin A, Masselon C et al. Beyond laser microdissection technology: follow the yellow brick road for cancer research. Am J Cancer Res 2014; 4 : 1-28.
151. Johnson NA, Hamoudi RA, Ichimura K et al. Application of array CGH on archival formalin-fi xed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest 2006; 86 : 968-78.
152. Tsongalis GJ, Peterson JD, de Abreu FB et al. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identifi cation of clinically actionable somatic mutations. Clin Chem Lab Med 2014; 52 : 707-14.
153. Capodieci P, Donovan M, Buchinsky H et al. Gene expression profi ling in single cells within tissue. Nat Methods 2005; 2 : 663-5.
154. Dry S, Grody WW, Papagni P. Stuck between a scalpel and a rock, or molecular pathology and legal-ethical issues in use of tissues for clinical care and research: what must a pathologist know? Am J Clin Pathol 2012; 137 : 346-55.
155. With CM, Evers DL, Mason JT. Regulatory and ethical issues on the utilization of FFPE tissues in research. Methods Mol Biol 2011; 724 : 1-21.
156. Hetzel JT, Huang CS, Coukos JA et al. Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am J Gastroenterol 2010; 105 : 2656-64.
157. Kahi CJ, Li X, Eckert GJ et al. High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. Gastrointest Endosc 2012; 75 : 515-20.
158. de Wijkerslooth TR, Stoop EM, Bossuyt PM et al. Differences in proximal serrated polyp detection among endoscopists are associated with variability in withdrawal time. Gastrointest Endosc 2013; 77 : 617-23.
159. Nishihara R, Wu K, Lochhead P et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369 : 1095-105.
160. Arain MA, Sawhney M, Sheikh S et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol 2010; 105 : 1189-95.
161. Burnett-Hartman AN, Passarelli MN, Adams SV et al. Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol 2013; 177 : 625-37.
162. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113 : 779-88.
163. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002; 101 : 403-8.
164. Carethers JM. One colon lumen but two organs. Gastroenterology 2011; 141 : 411-2.
165. Phipps AI, Buchanan DD, Makar KW et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012; 21 : 1792-8.
166. Rosty C, Young JP, Walsh MD et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013; 8 : e65479.
167. Phipps AI, Lindor NM, Jenkins MA et al. Colon and rectal cancer survival by tumor location and microsatellite instability: the colon cancer family registry. Dis Colon Rectum 2013; 56 : 937-44.
168. Zauber P, Huang J, Sabbath-Solitare M et al. Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancer's proximities to each other. J Mol Diagn 2013; 15 : 652-60.
169. Yamauchi M, Lochhead P, Morikawa T et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012; 61 : 794-7.
170. Li X, Leblanc J, Truong A et al. A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface. PLoS One 2011; 6 : e26542.
171. Colditz GA. Ensuring long-term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control. Cancer Causes Control 2010; 21 : 649-56.
172. Ogino S, King EE, Beck AH et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol 2012; 176 : 659-67.
173. Kuller LH. Invited Commentary: The 21st century epidemiologist-a need for different training? Am J Epidemiol 2012; 176 : 668-71.
174. Ogino S, Beck AH, King EE et al. Ogino et al. respond to " The 21st century epidemiologist ". Am J Epidemiol 2012; 176 : 672-4.